We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
University researchers have found a naturally occurring compound, known as hydroquinine, has bacterial killing activity against several microorganisms.
Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a pressing need for the development of new antimicrobial drugs to combat infections.
A new study by scientists from the University of Portsmouth and Naresuan and Pibulsongkram Rajabhat Universities in Thailand explored whether hydroquinine, which is found in the bark of some trees, could inhibit any bacterial strains. Hydroquinine is already known to be an effective agent against malaria in humans, but until now there has been little investigation into its drug-resistant properties.
The findings, published in the Tropical Medicine and Infectious Disease journal, suggest the antimicrobial properties of the organic compound make it a potential candidate for future clinical investigation.
Using bacterial killing experiments, we found that hydroquinine was able to kill several microorganisms including the common multidrug-resistant pathogen pseudomonas aeruginosa.
Characteristically, we also discovered that one of the main mechanisms used by these bacteria to escape killing activity of the drug was upregulated with treatment - indicating a robust response from the bacteria.
By studying this compound further, our hope is that it may in future offer another line of treatment in combatting bacterial infections."
Dr Robert Baldock, School of Pharmacy and Biomedical Sciences, University of Portsmouth
Drug-resistant bacteria occur in more than 2.8 million infections and are responsible for 35,000 deaths per year. Common antibiotic-resistant "superbugs" cause diseases including sepsis, urinary tract infections, and pneumonia. Statistics show bloodstream infections with the bacteria - P. aeruginosa are associated with high mortality rates of between 30 and 50%.
The study recommends further investigation into the antimicrobial resistance properties and side effects of hydroquinine.
Dr Jirapas Jongjitwimol from the Department of Medical Technology at Naresuan University added: "Our future research aims to uncover the molecular target of hydroquinine. This would help our understanding of how the compound works against pathogenic bacteria and how it could potentially be used in a clinical setting."
Rattanachak, N., et al. (2022) Hydroquinine Possesses Antibacterial Activity, and at Half the MIC, Induces the Overexpression of RND-Type Efflux Pumps Using Multiplex Digital PCR in Pseudomonas aeruginosa. Tropical Medicine and Infectious Disease. doi.org/10.3390/tropicalmed7080156.
Posted in: Medical Science News | Medical Research News | Pharmaceutical News
Tags: Antibiotic, Antimicrobial Resistance, Bacteria, Compound, Drugs, fungi, Malaria, Medicine, Mortality, Pathogen, Pharmacy, Pneumonia, Public Health, Research, Sepsis
For World Sepsis Day 2022, News Medical speaks to Colin Graham, COO of Sepsis Research FEAT, about the importance of sepsis awareness, research, and potentially life-changing breakthroughs.
In this interview, News Medical speaks to Jeffrey Stogsdill, Ph.D., about his latest research exploring how microglia change their state to adapt to different areas of the brain.
Until recently, cells were typically counted on a reusable quartz hemocytometer.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022